Bortezomib in newly diagnosed multiple myeloma

被引：6
|
作者：
Berenson, James R. [1 ]
机构：
[1] Inst Myeloma & Bone Canc Res, W Hollywood, CA 90069 USA
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2009年 / 6卷 / 05期
关键词：
RANDOMIZED PHASE-III; COMBINATION THERAPY; PREDNISONE; MELPHALAN; TIME;
D O I：
10.1038/nrclinonc.2009.47
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Preclinical studies have shown that new agents such as bortezomib not only demonstrate anti-multiple-myeloma activity as single agents but also enhance the efficacy of both chemotherapy and steroids. a randomized trial has established that bortezomib not only improves response rates but also prolongs the lives of patients with multiple myeloma who are not candidates for high-dose chemotherapy.
引用
收藏
页码：255 / 256
页数：2
相关论文
共 50 条
  • [1] Bortezomib in newly diagnosed multiple myeloma
    James R. Berenson
    [J]. Nature Reviews Clinical Oncology, 2009, 6 : 255 - 256
  • [2] Optimising bortezomib in newly diagnosed multiple myeloma
    Rajkumar, S. Vincent
    [J]. LANCET ONCOLOGY, 2010, 11 (10): : 909 - 910
  • [3] Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma
    Laubach, Jacob P.
    Schlossman, Robert L.
    Mitsiades, Constantine S.
    Anderson, Kenneth C.
    Richardson, Paul G.
    [J]. EXPERT REVIEW OF HEMATOLOGY, 2011, 4 (01) : 51 - 60
  • [4] Bortezomib Plus Thalidomide for Newly Diagnosed Multiple Myeloma in China
    Chen, Shi-Lun
    Jiang, Bin
    Qiu, Lu-Gui
    Yu, Li
    Zhong, Yu-Ping
    Gao, Wen
    [J]. ANATOMICAL RECORD-ADVANCES IN INTEGRATIVE ANATOMY AND EVOLUTIONARY BIOLOGY, 2010, 293 (10): : 1679 - 1684
  • [5] Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
    Zafar, Mir Sadaqat Hassan
    Khan, Afaq Ahmed
    Aggarwal, Shyam
    Bhargava, Manorama
    [J]. SOUTH ASIAN JOURNAL OF CANCER, 2018, 7 (01) : 58 - 60
  • [6] Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma
    Liang, Dong
    Bai, Shenrui
    Feng, Demei
    Chen, Guanjun
    Liang, Yang
    Wang, Hua
    [J]. BMC CANCER, 2024, 24 (01)
  • [7] The Choice Of Regimens Based On Bortezomib For Patients With Newly Diagnosed Multiple Myeloma
    Yang, Li
    He, Jingsong
    Han, Xiaoyan
    Zheng, Gaofeng
    Zheng, Weiyan
    Wei, Guoqing
    Wu, Wenjun
    Ye, Xiujin
    Shi, Jimin
    Xie, Wanzhuo
    Li, Li
    Zhang, Jie
    Huang, Weijia
    Zhao, Yi
    Huang, He
    Zhang, Xuejin
    Fu, Jiaping
    Cai, Zhen
    [J]. BLOOD, 2013, 122 (21)
  • [8] Evaluation of a Generic Bortezomib Molecule in Newly Diagnosed Multiple Myeloma Patients
    Mersin, Sinan
    Geduk, Ayfer
    Mehtap, Ozgur
    Tarkun, Pinar
    Unal, Serkan
    Polat, Merve Gokcen
    Aygun, Kemal
    Yenihayat, Emel Merve
    Albayrak, Hayrunnisa
    Hacihanifioglu, Abdullah
    [J]. TURKISH JOURNAL OF HEMATOLOGY, 2021, 38 (03) : 211 - 217
  • [9] Combination Therapy Based on Bortezomib for Newly Diagnosed Multiple Myeloma Patients
    He, Jingsong
    Yang, Li
    Jin, Dian
    Lin, Xuanru
    Yang, Qianqian
    Han, Xiaoyan
    Zheng, Gaofeng
    Zheng, Weiyan
    Wei, Guoqing
    Wu, Wenjun
    Ye, Xiujin
    Shi, Jimin
    Xie, Wanzhuo
    Zhang, Jie
    Lin, Maofang
    Huang, He
    Cai, Zhen
    [J]. BLOOD, 2012, 120 (21)
  • [10] COMBINATION THERAPY BASED ON BORTEZOMIB FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
    Cai, C.
    He, J.
    Yang, Y.
    Han, H.
    Zheng, G.
    Zheng, W.
    Wei, W.
    Wu, W.
    Ye, Y.
    Shi, S.
    Xie, X.
    Li, L.
    Zhang, Z.
    Huang, H.
    Huang, H.
    Zhen, Z.
    [J]. HAEMATOLOGICA, 2012, 97 : 611 - 611
12345